This Profile in Personalized Medicine highlights Stephanie Yang, owner and co-founder of Accent Wellness Compounding Pharmacy in Subang Jaya, Selangor, Malaysia. She has been a proud PCCA member since 2011. Our new 2023 profiles ask pharmacy compounders how they incorporate PCCA’s Principles into their pharmacies.

We’re reviewing the distinctions between SuspendIt and SuspendIt Anhydrous, as well as how revisions to USP Chapter 795 will guide beyond use dates (BUDs) for aqueous and nonaqueous oral dosage forms.

FDA’s Guidance for Industry (GFI) on compounding for animals using bulk drug substances will be used in FDA inspections starting on April 1, 2023. Read the top five potential impacts on compounding for animal patients.

Access scientific studies, which include images and videos, conducted by PCCA researchers that evaluated properties and performance of SuspendIt Anhydrous.

Congratulations to Brad White, RPh and Paul White, RPh for being selected as our March Profile in Personalized Medicine.

Matt Martin, PharmD, BCSCP, PCCA Director of Clinical Services, reviews USP 797revisions and impacts on compounding pharmacies in the fourth of a four-part series.

Matt Martin, PharmD, BCSCP, PCCA Director of Clinical Services, reviews USP 797 revisions and impacts on compounding pharmacies in the third of a four-part series.

Congratulations to Michelle Gray, BScPharm, RPh, C4 HRT Specialist of Gray's Compounding Pharmacy in Kimberley, British Columbia for being awarded PCCA’s 2022 Canadian Pharmacist of the Year and our February Profile in Personalized Medicine.

PCCA Clinical Compounding Pharmacist Sebastian Denison, RPh, FAARM (candidate), updates a 2016 Apothagram article and shares heart healthy tips that reignite the libido.

Our four-part series continues with Part 2, USP 795 revisions and impacts on compounding pharmacies.